27559-59-7

Upstream product

• 65-49-6 4-Aminosalicylic acid 
• 74-88-4 methyl iodide 
• 50-00-0 formaldehyd 
• 4136-97-4 methyl 4-aminosalicylate 
• 67-56-1 methanol 
• 23050-91-1 4-(dimethylamino)-2-hydroxybenzoic acid 
• 77-78-1 dimethyl sulfate 

Downstream Products

• 852370-75-3 methyl 2-[1-(tert-butoxycarbonyl)piperidin-4-yloxy]-4-(N,N-dimethylamino)-benzoate 
• 1044218-09-8 α,α-diphenyl-4-(dimethylamino)salicyl alcohol 
• 1153685-72-3 C₁₄H₁₉NO₅ 
• 1193367-05-3 C₂₀H₂₅F₃N₄O₃ 
• 1143579-89-8 methyl 4-(dimethylamino)-2-hydroxy-5-iodobenzoate 
• 1404436-83-4 methyl 4-(dimethylamino)-2-hydroxy-5-((2-(trifluoromethyl)phenyl)ethynyl)benzoate 
• 1404436-92-5 methyl 6-hydroxy-3-iodo-1-methyl-2-(2-(trifluoromethyl)phenyl)-1H-indole-5-carboxylate 
• 1404436-59-4 6-hydroxy-3-iodo-1-methyl-2-(2-(trifluoromethyl)phenyl)-1H-indole-5-carboxylic acid 
• 1404437-02-0 methyl 3-((3,5-difluorophenyl)ethynyl)-6-hydroxy-1-methyl-2-(2-(trifluoromethyl)phenyl)-1H-indole-5-carboxylate 
• 1404436-62-9 3-((3,5-difluorophenyl)ethynyl)-6-hydroxy-1-methyl-2-(2-(trifluoromethyl)phenyl)-1H-indole-5-carboxylic acid 
• 1404436-84-5 methyl 4-(dimethylamino)-2-hydroxy-5-((3-(trifluoromethyl)phenyl)ethynyl)benzoate 
• 1404436-85-6 methyl 5-([1,1'-biphenyl]-4-ylethynyl)-4-(dimethylamino)-2-hydroxybenzoate 
• 1404436-87-8 methyl 4-(dimethylamino)-2-hydroxy-5-((4-(trifluoromethoxy)phenyl)ethynyl)benzoate 
• 1404436-88-9 methyl 4-(dimethylamino)-5-((3-fluorophenyl)ethynyl)-2-hydroxybenzoate 

Relevant academic research and scientific papers

Chromatography-free, Mitsunobu-triggered heterocyclizations of salicylhydroxamic acids to 3-hydroxybenzisoxazoles

The Mitsunobu reaction has become one of the most powerful tools to alkylate acidic pronucleophiles. A significant caveat of Mitsunobu chemistry, however, is that the reaction mixture is often plagued with purification problems owing to the phosphine oxide and hydrazine dicarboxylate by-products. In addition to the development of more readily separable Mitsunobu reagents, the product's physicochemical properties may be exploited to facilitate purification. In this regard, we present a swift and efficient preparation of 3-hydroxybenzisoxazoles by the Mitsunobu-triggered heterocyclizations of salicylhydroxamic acids, which can be isolated by an acid–base work-up. As expected, a range of functional groups was compatible with the chemistry.

TYROSINE PHOSPHATASE INHIBITORS AND USES THEREOF TO MODULATE THE ACTIVITY OF LYP

A variety of benzofurans and indole derivatives some with an acetyl linker are disclosed herein. These compounds are not highly charged at physiological pH and have good bioavailability characteristics. These compounds exhibit selective or at least preferential affinity for the active sites of various sub-sets of protein tyrosine phosphatases. The lymphoid- specific tyrosine phosphatase (Lyp) has received enormous attention because of the finding that a single- nucleotide polymorphism (SNP) in the gene (PTPN22) encoding Lyp is associated with several autoimmune diseases, including type I diabetes. Many of these compounds and pharmaceutically acceptable salts thereof are novel therapeutic compounds useful for the treatment of various diseases including a number of autoimmune diseases.

Salicylic acid based small molecule inhibitor for the oncogenic src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2)

The Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) plays a pivotal role in growth factor and cytokine signaling. Gain-of-function SHP2 mutations are associated with Noonan syndrome, various kinds of leukemias, and solid tumors. Thus, there is considerable interest in SHP2 as a potential target for anticancer and antileukemia therapy. We report a salicylic acid based combinatorial library approach aimed at binding both active site and unique nearby subpockets for enhanced affinity and selectivity. Screening of the library led to the identification of a SHP2 inhibitor II-B08 (compound 9) with highly efficacious cellular activity. Compound 9 blocks growth factor stimulated ERK1/2 activation and hematopoietic progenitor proliferation, providing supporting evidence that chemical inhibition of SHP2 may be therapeutically useful for anticancer and antileukemia treatment. X-ray crystallographic analysis of the structure of SHP2 in complex with 9 reveals molecular determinants that can be exploited for the acquisition of more potent and selective SHP2 inhibitors.

Synthesis and modeling of new benzofuranone histone deacetylase inhibitors that stimulate tumor suppressor gene expression

New benzofuranones were synthesized and evaluated toward NCI-H661 non-small cell lung cancer cells. Benzamide derivatives possessed micromolar antiproliferative and histone deacetylase inhibitory activities and modulate histone H4 acetylation. Hydroxamic acids were found to be potent nanomolar antiproliferative agents and HDAC inhibitors. Computational analysis presented a rationale for the activities of the hydroxamate derivatives. Impact of the HDAC inhibition on the expression of E-cadherin and the SEMA3F tumor suppressor genes revealed new promising compounds for lung cancer treatments.

Sequential removal of photolabile protecting groups for carbonyls with controlled wavelength

(Chemical Equation Presented) A group of robust and easy-to-make photolabile protecting groups (PPGs) for carbonyl compounds has been developed. Sequential removal of different PPGs is achieved via control of irradiation wavelength.

AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS

This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor. An example of a compound of formula (I) is (a).